• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西洛他唑(一种选择性环磷酸腺苷磷酸二酯酶抑制剂)对血管平滑肌收缩的影响。

Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle.

作者信息

Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H

机构信息

Department of Molecular and Cellular Pharmacology, Mie University School of Medicine, Japan.

出版信息

Pharmacology. 1988;36(5):313-20. doi: 10.1159/000138400.

DOI:10.1159/000138400
PMID:2841693
Abstract

The effects of cilostazol (OPC-13013, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quin olinone) on cyclic nucleotide metabolism and Ca2+-induced contraction of intact and skinned rabbit arterial smooth muscles were investigated. The concentrations of cilostazol producing 50% inhibition of cyclic adenosine monophosphate phosphodiesterase and Ca2+-dependent cyclic nucleotide phosphodiesterase were 0.4 microM and above 100 microM, respectively. This compound has no significant effect on adenylate cyclase in concentrations of up to 100 microM. Addition of cilostazol increased significantly the cAMP content without significant effect on cyclic guanosine monophosphate level of rabbit thoracic aorta in the presence of forskolin. Moreover, the ED50 value of cilostazol in relaxation of rabbit mesenteric arterial strips was decreased selectively by addition of 0.01 microM forskolin, which alone at this concentration has no effect on vascular contraction. Cilostazol of up to 30 microM did not suppress the Ca2+-induced contraction of the chemically skinned rabbit mesenteric artery. Therefore, cilostazol may produce the relaxation of intact vascular smooth muscle by its inhibition of cyclic adenosine monophosphate hydrolysis.

摘要

研究了西洛他唑(OPC - 13013,6 - [4 - (1 - 环己基 - 1H - 四氮唑 - 5 - 基)丁氧基]-3,4 - 二氢 - 2(1H)-喹啉酮)对完整和去皮的兔动脉平滑肌环核苷酸代谢及钙诱导收缩的影响。产生50%抑制环磷酸腺苷磷酸二酯酶和钙依赖性环核苷酸磷酸二酯酶的西洛他唑浓度分别为0.4微摩尔/升和高于100微摩尔/升。该化合物在浓度高达100微摩尔/升时对腺苷酸环化酶无显著影响。在存在福斯可林的情况下,添加西洛他唑可显著增加兔胸主动脉的环磷酸腺苷含量,而对环磷酸鸟苷水平无显著影响。此外,添加0.01微摩尔/升福斯可林可选择性降低西洛他唑对兔肠系膜动脉条舒张的半数有效剂量值,该浓度的福斯可林单独使用时对血管收缩无影响。高达30微摩尔/升的西洛他唑不抑制化学去皮的兔肠系膜动脉的钙诱导收缩。因此,西洛他唑可能通过抑制环磷酸腺苷水解而使完整的血管平滑肌舒张。

相似文献

1
Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle.西洛他唑(一种选择性环磷酸腺苷磷酸二酯酶抑制剂)对血管平滑肌收缩的影响。
Pharmacology. 1988;36(5):313-20. doi: 10.1159/000138400.
2
Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit.III型磷酸二酯酶抑制剂西洛他唑对组胺诱导的兔大脑中动脉[Ca2+]i升高及张力的影响。
Br J Pharmacol. 1998 Mar;123(5):869-78. doi: 10.1038/sj.bjp.0701699.
3
Effects of a water-soluble forskolin derivative (NKH477) and a membrane-permeable cyclic AMP analogue on noradrenaline-induced Ca2+ mobilization in smooth muscle of rabbit mesenteric artery.水溶性福斯高林衍生物(NKH477)和膜通透性环磷酸腺苷类似物对去甲肾上腺素诱导的兔肠系膜动脉平滑肌Ca2+动员的影响。
Br J Pharmacol. 1993 Nov;110(3):1117-25. doi: 10.1111/j.1476-5381.1993.tb13930.x.
4
Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.3型和4型磷酸二酯酶抑制剂对脑动脉作用的分析。
Eur J Pharmacol. 2004 Apr 5;489(1-2):93-100. doi: 10.1016/j.ejphar.2004.02.038.
5
Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.新型强效选择性磷酸二酯酶5抑制剂DMPPO的心血管效应:体内外特性研究
Br J Pharmacol. 1996 Jul;118(6):1377-84. doi: 10.1111/j.1476-5381.1996.tb15548.x.
6
Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits.磷酸二酯酶3抑制剂奥普力农对兔肠系膜小动脉和静脉的血管舒张作用。
Eur J Pharmacol. 1998 Jul 24;353(2-3):239-46. doi: 10.1016/s0014-2999(98)00406-3.
7
Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor.新型环磷酸腺苷特异性磷酸二酯酶抑制剂毛诃子素对大鼠主动脉的内皮依赖性舒张作用
Eur J Pharmacol. 1995 Jun 23;280(1):69-77. doi: 10.1016/0014-2999(95)00190-v.
8
OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.OPC - 13013,一种III型环核苷酸磷酸二酯酶抑制剂,可抑制培养的大鼠肝星状细胞的增殖和转分化。
Life Sci. 1999;64(23):2081-8. doi: 10.1016/s0024-3205(99)00157-5.
9
Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture.西洛他唑(一种环磷酸腺苷磷酸二酯酶抑制剂)对培养的大鼠主动脉平滑肌细胞增殖的影响。
J Cardiovasc Pharmacol. 1992 Dec;20(6):900-6. doi: 10.1097/00005344-199212000-00009.
10
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.西洛他唑(培达):一种环磷酸腺苷3型磷酸二酯酶和腺苷摄取的双重抑制剂。
Cardiovasc Drug Rev. 2001 Winter;19(4):369-86. doi: 10.1111/j.1527-3466.2001.tb00076.x.

引用本文的文献

1
Antithrombotic Therapy in Carotid Artery and Intracranial Artery Stent.颈动脉和颅内动脉支架置入术中的抗栓治疗
J Neuroendovasc Ther. 2025;19(1). doi: 10.5797/jnet.ra.2024-0014. Epub 2024 Apr 16.
2
In Vitro/In Vivo Correlation of Two Extended-Release Cilostazol Formulations.两种西洛他唑缓释制剂的体外/体内相关性
Pharmaceuticals (Basel). 2024 Jun 16;17(6):787. doi: 10.3390/ph17060787.
3
Two Cases Showing That Cilostazol Administration Leads to an Increase in Cerebral Blood Flow and Has a Positive Effect on Rehabilitation.
两例病例显示,西洛他唑给药可导致脑血流量增加,并对康复有积极作用。
Cureus. 2024 Mar 18;16(3):e56376. doi: 10.7759/cureus.56376. eCollection 2024 Mar.
4
The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis.西洛他唑,一种磷酸二酯酶-3 抑制剂,在动脉粥样硬化和血管生物学发展中的作用:综述与荟萃分析。
Int J Mol Sci. 2024 Feb 23;25(5):2593. doi: 10.3390/ijms25052593.
5
Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial.西洛他唑治疗轻度认知障碍的疗效和安全性:一项随机临床试验。
JAMA Netw Open. 2023 Dec 1;6(12):e2344938. doi: 10.1001/jamanetworkopen.2023.44938.
6
Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease.真实世界中,西洛他唑控释片治疗有症状外周动脉疾病患者的安全性和有效性。
Clin Drug Investig. 2023 Sep;43(9):729-738. doi: 10.1007/s40261-023-01302-6. Epub 2023 Aug 31.
7
Stress resilience-enhancing drugs preserve tissue structure and function in degenerating retina via phosphodiesterase inhibition.应激弹性增强药物通过抑制磷酸二酯酶来保护退化视网膜的组织结构和功能。
Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2221045120. doi: 10.1073/pnas.2221045120. Epub 2023 May 1.
8
Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.当代抗血小板和抗凝治疗用于二级卒中预防:当前文献和指南的叙述性综述。
Curr Neurol Neurosci Rep. 2023 May;23(5):235-262. doi: 10.1007/s11910-023-01266-2. Epub 2023 Apr 11.
9
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.脑卒中抗血小板治疗策略的选择:基于证据和实用的策略。
Curr Neurol Neurosci Rep. 2022 Nov;22(11):789-802. doi: 10.1007/s11910-022-01237-z. Epub 2022 Oct 13.
10
Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke.西洛他唑联合阿司匹林或氯吡格雷用于非心源性脑卒中国后二级预防的成本-效果分析。
J Am Heart Assoc. 2022 Jun 7;11(11):e024992. doi: 10.1161/JAHA.121.024992. Epub 2022 Jun 3.